Axcan To Pay Up To $230M For Rival Mpex
Specialty pharmaceuticals company Axcan Holdings Inc. said Thursday it had agreed to pay as much as $230 million to acquire Mpex Pharmaceuticals Inc. and develop Mpex's Aeroquin treatment for pulmonary infections...To view the full article, register now.
Already a subscriber? Click here to view full article